Reading time: 11 minutes

According to the International Diabetes Federation, China has the largest adult diabetes population in the world, with around 140 million people affected [1]. That clinical volume has meant that diabetes care at leading Chinese endocrinology centres — continuous glucose monitoring (CGM), insulin pumps, GLP-1 receptor agonists, SGLT-2 inhibitors, modern insulin analogues — is broadly aligned with the international standard of care, and metabolic surgery is a mature option at high-volume centres. This article works through what is and is not a sensible reason to travel to China for diabetes care, the drugs and devices that are actually available, the metabolic surgery pathway, typical costs, and how to hand care back to your home-country team.

1. Diabetes Is Not a Typical Cross-Border Indication — Plain Speaking

The day-to-day management of most type 2 diabetes — diet, exercise, oral medication, insulin titration — should be done at home. That’s a basic principle of chronic disease care; cross-border ping-pong is neither realistic nor necessary.

Scenarios where travelling to China can be worth considering:

  1. Complex type 1 or brittle diabetes that warrants in-depth CGM and closed-loop insulin pump evaluation
  2. Difficult-to-control type 2 diabetes with significant obesity (BMI ≥ 32.5) for metabolic surgery consideration
  3. Diabetes with multiple end-organ complications (eyes, kidney, neuropathy, foot) where a one-stop multidisciplinary assessment is useful
  4. Limited access at home to newer agents or devices (for example, supply constraints on higher-dose GLP-1 formulations in some countries)
  5. A second opinion from a leading Chinese centre, particularly for paediatric type 1, adolescent LADA, or suspected MODY

Scenarios that do not need international travel:

  1. Routine follow-up for stable type 2 diabetes
  2. Single drug adjustment
  3. Routine surveillance when glycaemic control is acceptable

2. Diabetes Drugs Available in China (Broadly Aligned With Global Standards)

Oral agents:

  1. Metformin (first-line)
  2. SGLT-2 inhibitors: dapagliflozin, empagliflozin, canagliflozin — all available
  3. DPP-4 inhibitors: sitagliptin, linagliptin, vildagliptin, others
  4. Sulphonylureas, TZDs, α-glucosidase inhibitors

Injectables:

  1. GLP-1 receptor agonists: semaglutide (Ozempic), dulaglutide, liraglutide, exenatide — all approved in China by the NMPA [2]
  2. GIP/GLP-1 dual receptor agonist: tirzepatide (Mounjaro) — approved in China
  3. Modern basal insulins: insulin degludec, glargine U100/U300, degludec/aspart co-formulation
  4. Rapid-acting insulins: insulin aspart, lispro, glulisine

For international patients, all of these are paid out of pocket; national insurance coverage applies only to Chinese residents.

3. CGM and Insulin Pumps

Continuous glucose monitors (CGM):

  1. Abbott FreeStyle Libre (Libre 2/3 generations) — available in China
  2. Medtronic Guardian series
  3. Several domestically manufactured CGM systems

Insulin pumps:

  1. Medtronic MiniMed 770G / 780G (hybrid closed-loop)
  2. Roche Accu-Chek Insight / Solo
  3. Several domestically manufactured pumps

Automated insulin delivery (AID) / closed-loop systems:

  1. Medtronic MiniMed 780G — available in China
  2. Selected research-grade closed-loop platforms at academic centres

4. Metabolic Surgery (Bariatric Surgery for Diabetes)

For difficult-to-control type 2 diabetes with significant obesity (BMI ≥ 32.5, or BMI ≥ 27.5 with poor glycaemic control), metabolic surgery is an established treatment option in both Chinese and international guidelines [3][4].

Main procedures:

Procedure Excess weight loss T2DM remission Risk profile
Laparoscopic sleeve gastrectomy (LSG) ~60–70% ~50–70% Lower
Laparoscopic Roux-en-Y gastric bypass (RYGB) ~65–80% ~70–85% Moderate (anastomosis, nutritional)
One-anastomosis gastric bypass (OAGB / mini-bypass) Similar to RYGB Similar to RYGB Moderate
Biliopancreatic diversion (BPD / DS) 70%+ Strongest glycaemic effect Highest nutritional risk

Hospitals to consider:

  1. First Affiliated Hospital of Jinan University (an early Chinese centre for bariatric and metabolic surgery)
  2. Shengjing Hospital of China Medical University, Department of Metabolic Surgery
  3. Shanghai Changzheng Hospital, Bariatric Surgery
  4. Beijing Friendship Hospital, Bariatric Surgery
  5. Shanghai Sixth People’s Hospital, Bariatric and Metabolic Surgery

Typical costs (USD, 1 USD = 6.5 RMB):

Procedure USD
Laparoscopic sleeve gastrectomy (LSG) 9,000–14,000
Laparoscopic Roux-en-Y gastric bypass (RYGB) 11,000–17,000

US reference: LSG typically USD 18,000–25,000; RYGB USD 23,000–30,000 [5].

5. Endocrinology Centres to Consider

Hospital City
China-Japan Friendship Hospital, Department of Endocrinology Beijing
Peking Union Medical College Hospital, Endocrinology Beijing
Shanghai Sixth People’s Hospital, Endocrinology and Metabolism Shanghai
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Endocrinology and Metabolism Shanghai
West China Hospital, Endocrinology and Metabolism Chengdu
Sun Yat-sen First Hospital, Endocrinology Guangzhou
Jiangsu Province Hospital, Endocrinology Nanjing

6. Typical Process

Complete diabetes assessment (5–7 days):

  1. Days 1–2: comprehensive endocrine assessment — HbA1c, fasting and post-prandial glucose, C-peptide, islet autoantibodies, renal function, urine microalbumin, fundus, neurological exam
  2. Days 2–4: 14-day CGM fitting (the CGM can travel home with you for continued data collection)
  3. Days 3–5: dietitian and diabetes educator review
  4. Days 5–7: treatment plan adjustment, education, discharge

Metabolic surgery (10–14 days):

  1. Days 1–3: preoperative assessment, anaesthesia review, endoscopy
  2. Day 4: laparoscopic surgery
  3. Days 5–8: inpatient stay and early recovery
  4. Days 9–14: post-discharge early follow-up, nutritional guidance, suture removal

7. Typical Costs (USD, 1 USD = 6.5 RMB)

Item Public tertiary international dept. High-end private
Complete diabetes assessment package 1,200–2,500 2,500–5,000
14-day CGM monitoring (device included) 250–500 400–800
Insulin pump (device + initiation training) 4,500–9,000 6,500–12,000
Single endocrinology specialist consultation 100–300 200–500
GLP-1 receptor agonist monthly cost 250–600 350–800
SGLT-2 inhibitor monthly cost 30–80 50–120

8. Handing Care Back to Your Home Country

  1. CGM data uploads continue to work globally (Abbott LibreView, Medtronic CareLink global accounts)
  2. Insulin pump consumables are typically obtainable at home
  3. Most Chinese prescriptions have generic equivalents at home
  4. The attending Chinese physician is typically willing to do remote follow-up for 6–12 months

9. What MedCareInChina Can and Cannot Do on the Diabetes Pathway

Our two products are Remote Consultation and In-China Accompanied Care.

  1. Remote Consultation: a USD 800 single-expert consultation with an endocrinologist who reviews your records and gives an initial view on suitability for in-China treatment
  2. In-China Accompanied Care: hospital accompaniment with translation through assessment, CGM fitting, insulin pump training, or metabolic surgery

What we do not do: long-term diabetes management (this is the job of your home-country physician), remote CGM data interpretation, cross-border drug transport.

10. Action Checklist

  1. Bring 6 months of glucose records, HbA1c trend, medication history, and complication screening results
  2. Engage a remote consultation to assess whether travelling makes sense
  3. Apply for an S2 visa
  4. Plan 5–14 days in China depending on the indication
  5. Before departure, confirm with your home-country physician that they are willing to take over follow-up
  6. After discharge, upload CGM data on schedule to your home-country physician

Sources

[1] International Diabetes Federation — IDF Diabetes Atlas: https://diabetesatlas.org/ [2] National Medical Products Administration of China — Approval records for semaglutide, tirzepatide, and other diabetes medications: https://www.nmpa.gov.cn/ [3] Chinese Diabetes Society and Chinese Society of Surgery — Chinese guidelines for surgical treatment of obesity and type 2 diabetes [4] American Diabetes Association — Standards of Care in Diabetes: https://diabetesjournals.org/care [5] American Society for Metabolic and Bariatric Surgery — Procedure references: https://asmbs.org/